Idorsia’s TRYVIO – First FDA-approved therapy to target the endothelin pathway for systemic hypertension - Candlesense
IDIA Fda approval

Idorsia’s TRYVIO – First FDA-approved therapy to target the endothelin pathway for systemic hypertension

Allschwil, Switzerland – August 28, 2025 Idorsia Ltd (SIX: IDIA) releases an OnDemand investor webcast outlining how TRYVIO™ (aprocitentan) – the first and only hypertension therapy targeting the endothelin pathway – fits into the treatment landscape for difficult-to-control hypertension. In addition, the company will host a live investor Q&A on September 8, 2025, following the American Heart Association's (AHA) Hypertension Scientific Sessions.

Related Questions

How will the FDA approval of TRYVIO™ impact Idorsia’s revenue forecasts and stock valuation? What market share can TRYVIO™ realistically capture versus existing antihypertensive classes such as ACE inhibitors, ARBs, and calcium‑channel blockers? What pricing, reimbursement, and margin assumptions are being used for TRYVIO™, and how could they affect the company’s long‑term cash‑flow outlook?
Find similar articles on Candlesense globenewswire